# Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer

Source: https://onco.cc/trials/nct06931626/  
OnCo record `nct06931626` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This study tests a PARP inhibitor; the registry reports that it is recruiting.

## Summary

The registry lists NCT06931626 as recruiting, last updated 2026-07-24. Enrolment is 10 planned participants, an estimate. Interventions: NMS-03305293, Temozolomide. Primary measures include Number of Participants with Adverse Events (AEs). No results are posted in the registry; this does not exclude separate publications.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-06
- Registry id: NCT06931626
- Phase: 1
- Setting: Study of NMS-03305293, a Non-Trapping PARP1-Specific PARP Inhibitor in Relapsed Small Cell Lung Cancer
- Sponsor: Nerviano Medical Sciences

## Sources

- ClinicalTrials.gov NCT06931626: https://clinicaltrials.gov/study/NCT06931626

## Connected records

- cancers: [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- targets: [PARP](https://onco.cc/targets/parp/)
- drugs: [NMS-03305293](https://onco.cc/drugs/nms-03305293/)

---
JSON: https://onco.cc/api/v1/entities/nct06931626.json